A Semi-Universal Assay Platform to Quantitate Vaccines with Potential Applications for Biotherapeutics

Abstract

The semi-universal Gyrolab assay allowed assay development without reagent labeling. The format could also be translated into a plate-based assay.

Use of a Microfluidic Platform To Evaluate and Predict Reagent Performance in Microtiter Plate-Based Immunoassays

“…Resource Comparison of Gyrolab-and Plate-Based Screening. We used a semi-universal Gyrolab assay 30 that allowed screening clone candidates without additional labeling. This format avoided any potential impact from reagent labeling and improved throughput by eliminating the labeling step when multiple antibodies or multiple targets were evaluated.…”

“…Microfluidics-based immunoassays emerge as an attractive, complementary option to meet challenges as described above primarily due to its small-scale operating volumes, low consumption of precious reagents (and samples), and ease with which to automate the workflow of the multistep immunoassays. − Indeed, microfluidic components and designs are part of various formats of SPR-based techniques, including Biacore. While the landscape of microfluidic immunoassays in development and in commercial markets is highly diverse, − the relatively mature, commercial Gyrolab system is a versatile microfluidic technique that can potentially address most of these requirements outlined above to support the screening and generation of critical immunoassay reagents. − …”